What is SNY's current stock price?

As of now, SNY is trading at $49.69, with a daily change of -0.32%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

SNY Stock Analysis & IQ Rating | Sanofi

SNY

Sanofi

$49.69

-$0.16 | -0.32%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$60.12

MKT CAP

$122.38B

52W Low

$44.62

VOL

$4.26M

P/E Ratio

11.56

AVG VOL

$2.37M

RSI

47.21

TREND

Sideways

SNY Stock IQ

Login to see Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

SNY Target Price

Login to display

Strengths

SNY Rewards

Trading below its fair value

SNY Rewards

Earnings are forecast to grow

SNY Price Performance

$49 (+1.41%)

$47.45 (+4.72%)

$48.55 (+2.35%)

$45.89 (+8.28%)

1year

6month

3month

1month

SNY Risk Level

SNY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

Low

LOW

HIGH

SNY Analysts Opinion

SNY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

SNY Analysts Opinion

SNY Analysts opinion is negative but has improved from the past 3 months

SNY Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

69%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

0%

100%

SNY Street Sentiment

SNY Street Sentiment is bullish and have negative views on the near-term outlook

SNY Performance Sentiment

Sentiments overview associated with SNY events and the stock performance.

69%

29%

Positive

Negative

24 out of 35
events present

10 out of 35
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$50.03

Resistance
Price

$45.07

Current Price Range

$52.34

Show methods +

Linked to SNY

IQ

Close Price

Change

PFE

3.94

25.57

+1.67%

NVS

4.27

133.72

+1.09%

LLY

4.13

1033.56

-1.20%

MRK

4.03

102.27

+1.19%

ABBV

4.12

230.24

+2.62%

SNY Latest Analysis +

Sanofi (SAN:CA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript.

Today

$49.69 | -0.32%

Activity

Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM Owing to the Increasing Prevalence Awareness and Advancements in Gene Therapies | DelveInsight. Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM Owing to the Increasing Prevalence Awareness and Advancements in Gene Therapies |. DelveInsightThe sickle cell disease marke

Today

$49.69 | -0.32%

Activity

Potential

Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript.

Today

$49.69 | -0.32%

Activity

ARWR: Multiple Data Readouts Ahead in 2026. By Business UpdateMultiple Data Readouts Ahead in 2026Following the recent approval of REDEMPLO® for the treatment of patients with familial chylomicronemia syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week following approval which is ahead of schedule. While the company is focused on a successful commercial launch there are a number

Mon Dec 1, 2025

$49.95 | +0.14%

Activity

Deutsche Bank Maintains a Buy Rating on Sanofi (SNY). Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25 setting a €110 price target. The same day Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of moderate-to-severe chronic [….]

Fri Nov 28, 2025

$49.88 | -0.30%

Activity

Rating

Sanofi Stock Drops After Confirming Raid Tax Fraud Investigation. Sanofi stock dropped Wednesday after French authorities raided the drugmakers Paris headquarters as part of a tax fraud investigation.The post Sanofi Stock Drops After Confirming Raid Tax Fraud Investigation appeared first on Investor'.s Business Daily.

Wed Nov 26, 2025

$50.03 | -0.50%

Momentum

Milestones Over Sales: The Sanofi Partnership Now Drives Novavaxs Outlook.

Wed Nov 26, 2025

$50.03 | -0.50%

Activity

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe. ) an unannounced visit on Tuesday as tax investigators accompanied by prosecutors and specialist aides searched the site amid a widening financial probe.French prosecutors confirmed that Sanofi is the focus of a preliminary investigation launched in January 2024 into alleged money laundering of tax fraud including potential involvement by an organized group and possible criminal conspiracy Le Monde .The company said it used

Tue Nov 25, 2025

$50.28 | +2.30%

Activity

Sanofi Paris HQ raided over tax fraud investigation involving Societe Generale.

Tue Nov 25, 2025

$50.28 | +2.30%

Activity

Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria. Sanofi and Regeneron'.s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria The unpredictable nature of chronic spontaneous urticaria leaves patients guessing when they'.ll have their next outbreak of disruptive debilitating hives and itch which can make life challenging said Dupixent

Tue Nov 25, 2025

$50.28 | +2.30%

Activity

FAQ About SNY Stock Insights

What is SNY current stock price?

What are SNY stock strengths?

What is SNY Risk Level?

What is SNY market cap and volume?

What is SNY current Stock IQ?

Should I buy SNY stock right now?

Is SNY a Strong Buy right now?

What does a 'Strong Buy' rating mean for SNY?

What does a 'Strong Sell' rating mean for SNY?

What factors influence SNY's Stock IQ?

Explore our SNY Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored SNY Stock Strategies
Effective Risk Management

FIND US ON

Receive our SNY Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

SNY

Sanofi

Current Price

$49.69

-$0.16 | -0.32%

52W High

$60.12

MKT CAP

$122.38B

52W Low

$44.62

VOL

$4.26M

P/E Ratio

11.56

AVG VOL

$2.37M

RSI

47.21

TREND

Sideways

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

SNY Rewards

Trading below its fair value

SNY Rewards

Earnings are forecast to grow

Linked to SNY

Symbol

IQ

Close

Change

PFE

3.94

25.57

+1.67%

NVS

4.27

133.72

+1.09%

LLY

4.13

1033.56

-1.20%

MRK

4.03

102.27

+1.19%

ABBV

4.12

230.24

+2.62%

SNY Price Performance

$49 (+1.41%)

$47.45 (+4.72%)

$48.55 (+2.35%)

$45.89 (+8.28%)

1year

6month

3month

1month

SNY Analysts Opinion

SNY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

SNY Analysts Opinion

SNY Analysts opinion is negative but has improved from the past 3 months

SNY Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

69%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

0%

100%

SNY Street Sentiment

SNY Street Sentiment is bullish and have negative views on the near-term outlook

SNY Risk Level

SNY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Risks Indicators

Investors losing confidence

Low

LOW

HIGH

SNY Performance Sentiment

Sentiments overview associated with SNY events and the stock performance.

69%

29%

Positive

Negative

24 out of 35
events present

10 out of 35
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$50.03

Resistance
Price

$45.07

Current Price Range

$52.34

Show methods +

SNY Stock IQ

Login to unlock Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

SNY Latest Analysis

Sanofi (SAN:CA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript.

Today

$49.69 | -0.32%

Activity

Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM Owing to the Increasing Prevalence Awareness and Advancements in Gene Therapies | DelveInsight. Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM Owing to the Increasing Prevalence Awareness and Advancements in Gene Therapies |. DelveInsightThe sickle cell disease marke

Today

$49.69 | -0.32%

Activity

Potential

Sanofi (SAN:CA) Presents at Evercore 8th Annual Healthcare Conference Transcript.

Today

$49.69 | -0.32%

Activity

ARWR: Multiple Data Readouts Ahead in 2026. By Business UpdateMultiple Data Readouts Ahead in 2026Following the recent approval of REDEMPLO® for the treatment of patients with familial chylomicronemia syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week following approval which is ahead of schedule. While the company is focused on a successful commercial launch there are a number

Mon Dec 1, 2025

$49.95 | +0.14%

Activity

Deutsche Bank Maintains a Buy Rating on Sanofi (SNY). Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25 setting a €110 price target. The same day Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of moderate-to-severe chronic [….]

Fri Nov 28, 2025

$49.88 | -0.30%

Activity

Rating

Sanofi Stock Drops After Confirming Raid Tax Fraud Investigation. Sanofi stock dropped Wednesday after French authorities raided the drugmakers Paris headquarters as part of a tax fraud investigation.The post Sanofi Stock Drops After Confirming Raid Tax Fraud Investigation appeared first on Investor'.s Business Daily.

Wed Nov 26, 2025

$50.03 | -0.50%

Momentum

Milestones Over Sales: The Sanofi Partnership Now Drives Novavaxs Outlook.

Wed Nov 26, 2025

$50.03 | -0.50%

Activity

Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe. ) an unannounced visit on Tuesday as tax investigators accompanied by prosecutors and specialist aides searched the site amid a widening financial probe.French prosecutors confirmed that Sanofi is the focus of a preliminary investigation launched in January 2024 into alleged money laundering of tax fraud including potential involvement by an organized group and possible criminal conspiracy Le Monde .The company said it used

Tue Nov 25, 2025

$50.28 | +2.30%

Activity

Sanofi Paris HQ raided over tax fraud investigation involving Societe Generale.

Tue Nov 25, 2025

$50.28 | +2.30%

Activity

Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria. Sanofi and Regeneron'.s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria The unpredictable nature of chronic spontaneous urticaria leaves patients guessing when they'.ll have their next outbreak of disruptive debilitating hives and itch which can make life challenging said Dupixent

Tue Nov 25, 2025

$50.28 | +2.30%

Activity

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of SNY. We're here to help you make informed investment decisions today.

FIND US ON

Receive our SNY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

SNY Stock trends

SNY Stock performance

SNY Stock analysis

SNY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing SNY

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

SNY Stock Analysis & IQ Rating | Sanofi

SNY Stock IQ

SNY Target Price

SNY Risk Level

SNY Analysts Opinion

SNY Street Sentiment

SNY Performance Sentiment

Technical Price Levels

Explore our SNY Stock insights

Receive our SNY Daily Alerts

SNY Street Sentiment

SNY Risk Level

Technical Price Levels

Discover SNY Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of SNY. We're here to help you make informed investment decisions today.

Receive our SNY Daily Alerts

SNY Runner Alarm